Research Areas 【 display / non-display 】

Research Areas 【 display / non-display 】

• Life sciences   Dermatology  

Affiliation 【 display / non-display 】

Affiliation 【 display / non-display 】

• Sapporo Medical University   医学部   助教  

Papers 【 display / non-display 】

Papers 【 display / non-display 】

• Successful treatment of acrodermatitis continua of Hallopeau by TYK2 inhibitor with every other day.

  Yuji Kan, Hisashi Uhara

  The Journal of dermatological treatment   35 ( 1 ) 2316239 - 2316239  2024.12  [International journal]

  DOI PubMed

• Successful treatment of nail psoriasis by switching to a TYK2 inhibitor after cyclosporine.

  Yuji Kan, Kouhei Horimoto, Hisashi Uhara

  The Journal of dermatology    2024.09  [International journal]

  DOI PubMed

• ガスクロマトグラフィー質量分析を用いた患者の皮膚病変部に由来する臭気成分候補の探索

  におい・かおり環境学会誌 ( 公益社団法人におい・かおり環境協会 ) 55 ( 5 ) 315 - 318 2024年09月    2024.09

• Efficacy and safety of switching to bilastine, an H1-antihistamine, in patients with refractory chronic spontaneous urticaria (H1-SWITCH): a multicenter, open-label, randomized, parallel-group comparative study.

  Atsushi Fukunaga, Yasumasa Kakei, Sae Murakami, Yuji Kan, Koji Masuda, Masatoshi Jinnin, Ken Washio, Hiroo Amano, Tohru Nagano, Akihisa Yamamoto, Toshihiro Otsuka, Shunsuke Takahagi, Motoi Takenaka, Naoko Ishiguro, Koremasa Hayama, Naoko Inomata, Yukinobu Nakagawa, Akiko Sugiyama, Michihiro Hide

  Frontiers in immunology   15   1441478 - 1441478  2024  [International journal]

  　View Summary

  BACKGROUND: For treating patients with refractory chronic spontaneous urticaria (CSU) resistant to standard doses of 2nd generation H1-antihistamines (H1AH) the International and Japanese guidelines recommend increasing H1AH dose. The latter also recommends switching to a different H1AH. This study explored if the efficacy of the standard dose of bilastine 20 mg is non-inferior to that of double-dose of H1AH in patients with refractory CSU. METHODS: This phase IV, multicenter, open-label, randomized, parallel-group trial evaluated the efficacy and safety of switching treatment to bilastine compared to treatment with a 2-fold dose of H1AH in patients with CSU refractory to standard dose H1AH. The primary endpoint was the mean total symptom score (TSS) at Day 5-7 after the start of administration. RESULTS: Treatment efficacy and safety were evaluated in 128 patients (bilastine, n=64; 2-fold dose of H1AH, n=64). The mean TSS at Day 5-7 after the start of administration was smaller than the non-inferiority margin of 0.8, demonstrating non-inferiority of the bilastine switching group to the double-dose H1AH group (0.17 (95% CI -0.32, 0.67)). No difference in Japanese version of Epworth Sleepiness Scale (JESS), DLQI, and urticaria activity score over 7 consecutive days (UAS7) was observed between the two groups. There were no serious adverse events in either group. H1AH-related adverse events occurred in 5 subjects (8 cases) and 2 subjects (3 cases) in the double-dose H1AH and bilastine groups, respectively. CONCLUSIONS: Switching treatment to bilastine demonstrated non-inferiority to a double-dose of H1AH in terms of efficacy in patients with CSU refractory to standard dose H1AH with a favorable safety profile. CLINICAL TRIAL REGISTRATION: https://jrct.niph.go.jp/latest-detail/jRCTs051180105, identifier jRCTs051180105.

  DOI PubMed

• 【アトピー性皮膚炎の役立つ最新情報】BNT162b2 mRNA(Pfizer-BioNTech) COVID-19ワクチン接種後のアトピー性皮膚炎様紅皮症

  菅 裕司, 半田 稔也, 小松 彩友香, 小栗 瑛実, 箕輪 智之, 宇原 久

  皮膚病診療 ( (株)協和企画 )  45 ( 11 ) 1012 - 1015  2023.11

  　View Summary

  ＜文献概要＞症例のポイント ・乾癬の既往がある男性がBNT162b2 mRNA(Pfizer-BioNTech) COVID-19ワクチン接種後,アトピー性皮膚炎様紅皮症となった.・病理組織像では非特異的な湿疹像で異型リンパ球の浸潤はなかった.・ステロイド内服依存状態からウパダシチニブに変更することで改善し,2年間再燃はなかった.

display all >>

Misc 【 display / non-display 】

Misc 【 display / non-display 】

• 食物依存性運動誘発性アナフィラキシーとの鑑別を要した汗アレルギーの1例

  織田 美琴, 菅 裕司, 勝賀瀬 なゆは, 畠山 瑞季, 静川 友里恵, 小菅 敦子, 前田 理沙子, 宇原 久

  日本皮膚科学会雑誌 ( (公社)日本皮膚科学会 )  134 ( 9 ) 2306 - 2306  2024.08

• 当科における円形脱毛症に対するバリシチニブの治療経験

  畠山 瑞季, 菅 裕司, 松田 宇充, 濱田 茉里奈, 織田 美琴, 安食 さえ子, 熊谷 綾子, 肥田 時征, 宇原 久

  日本皮膚科学会雑誌 ( (公社)日本皮膚科学会 )  134 ( 6 ) 1657 - 1657  2024.05

• ざ瘡症状が遷延した慢性再発性多発性骨髄炎(CRMO)の1例

  半田 稔也, 菅 裕司, 熊谷 綾子, 肥田 時征, 宇原 久, 木澤 敏毅, 岡田 葉平

  日本皮膚科学会雑誌 ( (公社)日本皮膚科学会 )  134 ( 6 ) 1660 - 1660  2024.05

• 菌状息肉症に対するデニロイキンジフチトクスの治療経験

  阿部 史華, 菅 裕司, 勝賀瀬 なゆは, 前田 理沙子, 松田 宇充, 執行 遥香, 小栗 瑛実, 安食 さえ子, 熊谷 綾子, 宇原 久

  日本皮膚科学会雑誌 ( (公社)日本皮膚科学会 )  134 ( 5 ) 1545 - 1545  2024.05

• 周術期アナフィラキシーの疑いで紹介された17例の皮膚テストの結果

  静川 友里恵, 菅 裕司, 熊谷 綾子, 安食 さえ子, 小栗 瑛実, 織田 美琴, 阿部 史華, 畠山 瑞季, 小菅 敦子, 宇原 久

  日本皮膚科学会雑誌 ( (公社)日本皮膚科学会 )  134 ( 6 ) 1657 - 1657  2024.05

display all >>

Research Projects 【 display / non-display 】

Research Projects 【 display / non-display 】

• Expression of skin barrier protein cystatin A analysis in the AD patients skin

  Grant-in-Aid for Young Scientists (B)

  Project Year :

  2014.04

  -

  2017.03

   

  KAN YUJI, YAMASHITA Toshiharu, SUMIKAWA Yasuyuki, YOKOTA Shinichi

  　View Summary

  Cystatin A is present in skin and known as protein with the antiviral effect. After immunostaining cystatin A of the atopic dermatitis (AD) patients skin of 30 cases, we compared AD lesion and normal AD skin with healthy part. Both cystatin of AD skin lesion and the healthy part was found to have attenuated as compared with normal skin in expression of cystatin A. After transmitting a herpesvirus 1、2 and adenoviral type 5 to HaCaT cells, cystatin A inhibited these viral DNA and protein synthesis. It was thought to become easy to develop for herpesvirus infection including the Kaposi varicelliform eruption as a result of decrease of barrier function. Cystatin A can become the new therapy for these infections in the future.